Get the Stockscreener App
1.59
7.43%
0.11
After Hours:
1.59
Zentalis Pharmaceuticals Inc stock is traded at $1.59, with a volume of 1.48M.
It is up +7.43% in the last 24 hours and up +18.66% over the past month.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
See More
Previous Close:
$1.48
Open:
$1.5
24h Volume:
1.48M
Relative Volume:
1.60
Market Cap:
$114.70M
Revenue:
-
Net Income/Loss:
$-292.19M
P/E Ratio:
-0.3502
EPS:
-4.54
Net Cash Flow:
$-208.41M
1W Performance:
+10.42%
1M Performance:
+18.66%
6M Performance:
-34.57%
1Y Performance:
-50.31%
1-Day Range:
$1.50
$1.6994
1-Week Range:
$1.36
$1.6994
52-Week Range:
$1.01
$5.44
Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile
Name
Zentalis Pharmaceuticals Inc
Sector
Industry
Phone
(858) 263-4333
Address
10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY
Compare ZNTL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZNTL
Zentalis Pharmaceuticals Inc
|
1.59 | 106.76M | 0 | -292.19M | -208.41M | -4.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-24 | Upgrade | Wedbush | Underperform → Neutral |
| Jun-20-24 | Downgrade | UBS | Buy → Neutral |
| Jun-18-24 | Downgrade | Jefferies | Buy → Hold |
| Jun-18-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-18-24 | Downgrade | Wedbush | Neutral → Underperform |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Nov-08-23 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-07-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jul-12-22 | Initiated | Cowen | Outperform |
| Apr-06-22 | Initiated | Wells Fargo | Overweight |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-30-21 | Initiated | Stifel | Buy |
| Sep-29-21 | Initiated | Oppenheimer | Outperform |
| May-21-21 | Initiated | UBS | Buy |
| Jan-20-21 | Initiated | Wedbush | Outperform |
| Sep-29-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-27-20 | Initiated | H.C. Wainwright | Buy |
| Apr-28-20 | Initiated | Guggenheim | Buy |
| Apr-28-20 | Initiated | Jefferies | Buy |
| Apr-28-20 | Initiated | Morgan Stanley | Overweight |
| Apr-28-20 | Initiated | SVB Leerink | Outperform |
View All
Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News
Is Zentalis Pharmaceuticals Inc. a good stock for dollar cost averaging2025 Technical Overview & Weekly Momentum Stock Picks - thegnnews.com
How to use a screener to detect Zentalis Pharmaceuticals Inc. breakoutsWeekly Risk Report & Community Consensus Picks - Newser
How to integrate Zentalis Pharmaceuticals Inc. into portfolio analysis toolsJuly 2025 Earnings & Precise Buy Zone Identification - Newser
Zentalis Pharmaceuticals Inc. stock outlook for YEARJuly 2025 PreEarnings & Growth Focused Entry Point Reports - Newser
Has Zentalis Pharmaceuticals Inc. Stock Ever Crashed Historical Volatility ReviewMarket Performance Summary & Risk Controlled Swing Alerts - Newser
Applying Wyckoff theory to Zentalis Pharmaceuticals Inc. stockWatch List & Stepwise Entry and Exit Trade Signals - Newser
Custom watchlist performance reports with Zentalis Pharmaceuticals Inc.July 2025 Selloffs & Safe Entry Point Identification - Newser
What makes Zentalis Pharmaceuticals Inc. stock price move sharplyMarket Movers & Risk Managed Trade Strategies - sundaytimes.kr
Analyzing recovery setups for Zentalis Pharmaceuticals Inc. investorsWeekly Stock Analysis & Community Verified Trade Signals - Newser
Can a trend reversal in Zentalis Pharmaceuticals Inc. lead to recovery2025 Growth vs Value & Low Risk Profit Maximizing Plans - Newser
Published on: 2025-08-15 04:37:23 - Newser
What are the risks of holding Zentalis Pharmaceuticals Inc.Profit Target & Consistent Income Trade Recommendations - kangso.co.kr
Sentiment analysis tools applied to Zentalis Pharmaceuticals Inc.July 2025 News Drivers & Proven Capital Preservation Tips - Newser
Using economic indicators to assess Zentalis Pharmaceuticals Inc. potentialWeekly Investment Report & Fast Momentum Entry Tips - Newser
Price Clustering Detected in Zentalis Pharmaceuticals Inc. StockMarket Risk Analysis & Fast Entry Momentum Alerts - 선데이타임즈
Using flow based indicators on Zentalis Pharmaceuticals Inc.July 2025 Outlook & Daily Growth Stock Investment Tips - Newser
Is Zentalis Pharmaceuticals Inc. stock a smart retirement pickROI Focused Stock Opportunities - mustnews.co.kr
Wells Fargo & Company Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price - MarketBeat
Leerink Partnrs Has Pessimistic View of ZNTL Q3 Earnings - Defense World
Equities Analysts Offer Predictions for ZNTL Q3 Earnings - Defense World
When is the best time to exit Zentalis Pharmaceuticals Inc.Predictive AI Signals for Short-Term Trading - Newser
Watch for Trend Continuation in Zentalis Pharmaceuticals Inc. Next WeekTechnical Stock Breakout Predictions Signal Entry Points - beatles.ru
Zentalis price target lowered to $5 from $6 at Wells Fargo - MSN
Wall Street Zen Upgrades Zentalis Pharmaceuticals (NASDAQ:ZNTL) to Hold - Defense World
Why Zentalis Pharmaceuticals Inc. stock attracts strong analyst attentionFree Trend Analysis for Safer Trades - Newser
ZNTL: Wells Fargo Adjusts Price Target, Maintains Rating | ZNTL Stock News - GuruFocus
Zentalis Pharmaceuticals: Hold Rating Amid Delayed Catalysts and Market Skepticism - TipRanks
Strategic Advancements and Promising Clinical Data Support Buy Rating for Zentalis Pharmaceuticals - TipRanks
Zentalis Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $5 to $10 - 富途牛牛
Zentalis Pharmaceuticals Reports Improved Financial Results - TipRanks
Zentalis (ZNTL) Q2 Loss Narrows 70% - The Motley Fool
Zentalis (ZNTL) Q2 Loss Narrows 70% - AOL.com
Zentalis Pharmaceuticals Inc Stock (ZNTL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.41%
0.88%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):